WHO Marks Global Cervical Cancer Elimination Day as CDC Expands National Adolescent HPV Vaccination Push Toward 2030 Goals
On World Cervical Cancer Elimination Day, the World Health Organization mobilized health ministries across 110 nations, while the CDC and HHS unveiled a major national initiative to raise U.S. adolescent HPV vaccination rates to 90% by 2030.

GENEVA / ATLANTA — Demonstrating unprecedented international unity against a major preventable malignancy, health authorities across more than 110 nations joined the World Health Organization on Wednesday to mark World Cervical Cancer Elimination Day. Convening a high-level ministerial summit in Geneva, WHO Director-General Dr. Tedros Adhanom Ghebreyesus celebrated monumental strides in cervical cancer prevention while issuing an urgent call to close persistent global equity gaps in vaccine supply and diagnostic screening.
The global campaign is anchored in the WHO's ambitious 90–70–90 targets for 2030: ensuring that 90 percent of girls are fully vaccinated with the human papillomavirus (HPV) vaccine by age 15, 70 percent of women are screened with high-performance HPV DNA testing by ages 35 and 45, and 90 percent of women identified with cervical disease receive prompt, high-quality clinical treatment. Global health leaders highlighted that achieving these targets could avert more than 62 million deaths over the next century, transforming cervical cancer into the first human cancer ever eliminated from the planet.
In the United States, the Department of Health and Human Services (HHS) and the Centers for Disease Control and Prevention (CDC) marked the day by unveiling the 'National HPV Immunization Acceleration Initiative.' The federal program allocates $450 million in community public health grants to support school-based vaccination drives, mobile rural health clinics, and clinician educational outreach, specifically targeting rural and underserved counties where adolescent HPV completion rates have lagged behind national averages.
'Cervical cancer is almost completely preventable through modern immunization and early screening, yet thousands of American women still lose their lives to this disease every year,' stated CDC Director Dr. Mandy Cohen during a morning public health briefing in Atlanta. 'By modernizing our public health infrastructure, debunking misinformation, and making the HPV vaccine seamlessly accessible to every adolescent regardless of socioeconomic status, we have the historic power to eliminate this scourge once and for all.'
The federal initiative also expands access to FDA-approved at-home HPV self-sampling kits for adult women enrolled in Medicaid, removing geographic and logistical barriers that prevent millions of women from attending routine gynecological exams. Survivor advocacy organizations, medical associations, and international health leaders praised the initiative, emphasizing that science and political determination have finally aligned to make cancer elimination an achievable reality.
Related Coverage

FDA Approves Breakthrough Breast Cancer Therapy Wilserdly and First At-Home Sublingual Treatment for Acute Agitation
Federal regulators issued landmark clearances on Tuesday, approving Genentech's targeted oral therapy Wilserdly for advanced metastatic breast cancer alongside authorizing Teva's IGALMI sublingual film as the first at-home prescription for acute psychiatric agitation.

U.S. Measles Toll Exceeds 5,400 Cases and 10 Deaths as FDA Mandates Class-Wide Vision Loss Warnings on Popular GLP-1 Medications
Federal public health authorities reported on Monday that the national measles outbreak has climbed past 5,400 confirmed infections across 38 states, while the FDA announced mandatory boxed warnings on blockbuster GLP-1 weight-loss drugs regarding rare but irreversible non-arteritic anterior ischemic optic neuropathy (NAION).

FDA Approves Landmark Durvalumab and Padcev Immunotherapy Combination for Muscle-Invasive Bladder Cancer
Federal regulators greenlighted a groundbreaking dual-therapy regimen following landmark Phase 3 VOLGA trial data demonstrating unprecedented event-free and overall survival gains for patients ineligible for conventional chemotherapy.